Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PIPAC after curative surgery for high-risk colorectal cancer
2024-513376-17-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, levoleucovorin and fluorouracil in colorectal cancer (CRC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Peritoneal metastasis-free survival. Planned start Nov 2020; status: authorised.
02
Drugs
oxaliplatinlevoleucovorinfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-513376-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513376-17-00.